Bioiberica opens a new manufacturing plant for specialized heparin and heparin derivatives
Bioiberica just opened a new production site of Heparin derivatives within the expansion plan of its Science portfolio.
This new plant is added to the new and modern production site of crude heparin. It is based at our headquarters in Palafolls (Barcelona) and will focus exclusively on the industrial production of Heparin Lithium or Heparin Ammonium and any other derivatives that our customers may need. With this new plant, Bioiberica forges ahead with its commitment to expand its specialized product range for all companies and projects requiring specialized heparins or heparin derivatives.
Related News
A crucial initiative to prevent shortages of critical medicines in the European Union.
The 28th Symposium on Glycosaminoglycans, an internationally renowned scientific event focusing on glycosaminoglycans, will be sponsored by
- Bioiberica produces 20% of the world's Heparin API.
- Heparin saves around a hundred million lives every year.
- One out of every 5 doses of heparin administered in the world comes from Bioiberica.